• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    In8Bio Inc (NQ: INAB )

    0.8622 -0.0104 (-1.19%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 92,832
    Open 0.8600
    Bid (Size) 0.8555 (50)
    Ask (Size) 0.8970 (2)
    Prev. Close 0.8726
    Today's Range 0.8499 - 0.8847
    52wk Range 0.6500 - 2.480
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga

    Performance

    YTD
    -34.68%
    -34.68%
    1 Month
    -2.18%
    -2.18%
    3 Month
    -17.10%
    -17.10%
    6 Month
    -35.66%
    -35.66%
    1 Year
    -45.77%
    -45.77%

    More News

    Read More
    Gold Gains 1%; US Consumer Sentiment Falls In June
    Via Benzinga
    INAB Stock Earnings: IN8bio Misses EPS for Q1 2024
    Via InvestorPlace
    INAB Stock Earnings: IN8bio Misses EPS for Q4 2023
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
    From IN8bio, Inc
    Via GlobeNewswire
    IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
    From IN8bio, Inc
    Via GlobeNewswire
    IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
    From IN8bio, Inc
    Via GlobeNewswire
    IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
    From IN8bio, Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential
    Via Benzinga
    Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
    From IN8bio, Inc
    Via GlobeNewswire
    IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
    From IN8bio, Inc
    Via GlobeNewswire
    IN8bio to Present at Upcoming Investor Conferences
    From IN8bio, Inc.
    Via Business Wire
    IN8bio’s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
    Via News Direct
    IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Exposures Product Safety
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.